Blocking c-Met–mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
Nature Medicine2016Vol. 22(2), pp. 194–201
Citations Over TimeTop 1% of 2016 papers
Yi Du, Hirohito Yamaguchi, Yongkun Wei, Jennifer L. Hsu, Hung-Ling Wang, Yi‐Hsin Elsa Hsu, Wan-Chi Lin, Wen-Hsuan Yu, Paul G. Leonard, Gilbert R. Lee, Mei‐Kuang Chen, Katsuya Nakai, Ming‐Chuan Hsu, Chun‐Te Chen, Ye Sun, Yun Wu, Wei-Chao Chang, Wen-Chien Huang, Chien‐Liang Liu, Yuan-Ching Chang, Chung‐Hsuan Chen, Morag Park, Philip Jones, Gabriel N. Hortobágyi, Mien‐Chie Hung
Related Papers
- → The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma(2018)96 cited
- → Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor(2021)28 cited
- → OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells(2022)13 cited
- → Data from Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity(2023)
- → Abstract 6098: Genome wide CRISPR screen reveals genetic vulnerabilities of next generation PARP1 inhibitor AZD5305(2023)